Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 10/20 | 1.00 |
| ▸ | F2 | P00734 | 10/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 9/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 9/20 | 1.00 |
| ▸ | PROC | P04070 | 3/20 | 0.87 |
| ▸ | F9 | P00740 | 2/20 | 0.87 |
| ▸ | KLK1 | P06870 | 1/20 | 0.87 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.86 |
| ▸ | CFH | P08603 | 1/20 | 0.86 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7749603 | 0.94 | PRSS1 (0.88) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL29825652 | 0.93 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL3052253 | 0.93 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL31067656 | 0.93 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL29377504 | 0.92 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7742478 | 0.92 | F10 (0.89) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL7746996 | 0.89 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL14318599 | 0.86 | F10 (1.00) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL3832849 | 0.86 | F2 (0.79) | F10PRSS1F2PRSS2PRSS3 | |
| SCHEMBL19706432 | 0.84 | F10 (0.83) | F10PRSS1F2PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009939-A1 | CONCURRENT DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20100009939-A1 | CONCURRENT DRUGS | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-01-14 | — | — | US | disclosed |
| US-20070105825-A1 | Concurrent drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| US-20070105825-A1 | Concurrent drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009939-A1 | CONCURRENT DRUGS | CYP3A5, HPSE, SLC9A5 | F10 64/4885PRSS1 347/4885F2 26/4885 |
| US-20070105825-A1 | Concurrent drugs | CYP3A5, HPSE, SLC9A5 | F10 64/4885PRSS1 347/4885F2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.